DSM Sinochem Pharmaceuticals announces licensing agreement for intellectual property assets related to the manufacture of beta lactam antibiotics

Rijswijk, NETHERLANDS, March 17, 2017 /PRNewswire/ -- DSM Sinochem Pharmaceuticals (DSP) and Sandoz (a Novartis Division) announced today that they have executed a definitive agreement licensing certain DSP intellectual property assets for the manufacture of beta lactam antibiotics.

The license agreement provides Sandoz a non-exclusive, worldwide license to certain patents including, inter alia, U.S. 8,541,199 B2 and EP 1,610,766 B1, granting freedom to operate to develop and commercialize its various beta lactam products and allows for the production of new enzymes for the sustainable manufacture of amoxicillin.

Karl Rotthier, CEO of DSP stated: "DSP is pleased to have Sandoz as a licensee of our innovative, sustainable and environmentally friendly amoxicillin manufacturing technology. As part of our commitment to fight antimicrobial resistance through minimizing the environmental impact from antibiotics manufacturing, DSP is actively seeking to promote green, enzymatic routes for production of amoxicillin and other antibiotics, utilizing our patented technology. This license agreement further validates the strength of DSP's intellectual property portfolio regarding enzymatically produced antimicrobials."

The commitment to reduce environmental impact from the production of antibiotics is also laid out in the Industry Roadmap for Progress on Combating Antimicrobial Resistance, signed by DSP, Novartis and 11 other leading pharmaceutical companies at the United Nations General Assembly in New York in September 2016.

About DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

Please visit www.dsm-sinochem.com for more information or contact
DSM Sinochem Pharmaceuticals Corporate Communications
Alice Beijersbergen, Head of Corporate Communications
E-Mail: [email protected]
www.dsm-sinochem.com

SOURCE DSM Sinochem Pharmaceuticals

Related Links

http://www.dsm-sinochem.com